Cargando…

Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC

INTRODUCTION: Patients with early NSCLC (eNSCLC) who experience recurrence are associated with worse survival outcomes, but the economic burden of recurrence is not well characterized. This study evaluated the incremental health care resource utilization and costs of recurrence in Medicare patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jay M., Wang, Rongrong, Johnson, Ann, Ogale, Sarika, Kent, Matthew, Lee, Janet S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050774/ https://www.ncbi.nlm.nih.gov/pubmed/37007869 http://dx.doi.org/10.1016/j.jtocrr.2023.100487

Ejemplares similares

Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020)

Estimating recurrences prevented and costs avoided with atezolizumab in early non‐small cell lung cancer in the United States
por: Sharma, Rishika, et al.
Publicado: (2022)

Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020)

Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer
por: Das, Millie, et al.
Publicado: (2023)

The economic burden of Parkinson disease among Medicare beneficiaries
por: Albarmawi, Husam, et al.
Publicado: (2022)

Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing
por: Sheinson, Daniel M., et al.
Publicado: (2021)

Economic burden of hospitalizations of Medicare beneficiaries with heart failure
por: Kilgore, Meredith, et al.
Publicado: (2017)

General Revenue Financing of Medicare: Who Will Bear the Burden?
por: Johnson, Janet L., et al.
Publicado: (1982)

Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population
por: Williams, Setareh A., et al.
Publicado: (2020)

Long-Term Recurrence of Completely Resected NSCLC
por: Masago, Katsuhiro, et al.
Publicado: (2020)

Economic Burden of Postoperative Neurocognitive Disorders Among US Medicare Patients
por: Boone, M. Dustin, et al.
Publicado: (2020)

Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain
por: De Castro, Javier, et al.
Publicado: (2023)

Incidence and Economic Burden of Intertrochanteric Fracture: A Medicare Claims Database Analysis
por: Adeyemi, Ayoade, et al.
Publicado: (2019)

Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC
por: Patnaik, Santosh K., et al.
Publicado: (2021)

The Role of Lymphadenectomy in Early-Stage NSCLC
por: Manfredini, Beatrice, et al.
Publicado: (2023)

Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population
por: Sethi, Sanjay, et al.
Publicado: (2022)

Risk factors of postoperative recurrences in patients with clinical stage I NSCLC
por: Chen, Ying-Yi, et al.
Publicado: (2014)

Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers
por: Ruel, Louis-Jacques, et al.
Publicado: (2022)

A prediction model integrated genomic alterations and immune signatures of tumor immune microenvironment for early recurrence of stage I NSCLC after curative resection
por: Hu, Chunhong, et al.
Publicado: (2022)

The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings
por: Neuenschwander, James F., et al.
Publicado: (2023)

Contemporary economic burden in a real‐world heart failure population with Commercial and Medicare supplemental plans
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

SAT233 Clinical And Economic Burden Of Postsurgical Chronic Hypoparathyroidism: A US Medicare Retrospective Analysis
por: Noori, Wahidullah, et al.
Publicado: (2023)

Predictors of Recurrence after Curative Resection in Patients with Early-Stage Non-Small Cell Lung Cancer
por: Lee, Sang Hee, et al.
Publicado: (2015)

The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational cohort study
por: Sibbel, Scott, et al.
Publicado: (2016)

Economic Burden in Direct Costs of Concomitant Chronic Obstructive Pulmonary Disease and Asthma in a Medicare Advantage Population
por: Blanchette, Christopher M., et al.
Publicado: (2008)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
por: Friedlaender, Alex, et al.
Publicado: (2020)

The burden of metastatic disease of the femur on the Medicare system
por: Gendi, Kirollos, et al.
Publicado: (2016)

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
por: Crandall, John P., et al.
Publicado: (2017)

Medicare hospice benefit: Early program experiences
por: Davis, Feather Ann
Publicado: (1988)

The Medicare Economic Index: Its Background and Beginnings
por: Dutton, Benson L., et al.
Publicado: (1981)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

APE1 may influence CD4+ naïve T cells on recurrence free survival in early stage NSCLC
por: Li, Yanping, et al.
Publicado: (2021)

Clinical burden of recurrent Clostridioides difficile infection in the medicare population: A real-world claims analysis
por: Feuerstadt, Paul, et al.
Publicado: (2022)

What is the optimal management of potentially resectable stage III-N2 NSCLC? Results of a fixed-effects network meta-analysis and economic modelling
por: Evison, Matthew, et al.
Publicado: (2023)

The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
por: Garris, Cindy, et al.
Publicado: (2015)

Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
por: Lee, Jay M., et al.
Publicado: (2021)

Surgeons' preference sublobar resection for stage I NSCLC less than 3 cm
por: Huang, Chien‐Sheng, et al.
Publicado: (2020)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

Analysis of predictive factors of unforeseen nodal metastases in resected clinical stage I NSCLC
por: Gallina, Filippo Tommaso, et al.
Publicado: (2023)

Clinical and economic outcomes after surgical aortic valve replacement in Medicare patients
por: Clark, Mary Ann, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_segvm9q3jdcr7e1cpn9bobsjdj